Meiji submits additional application in Japan for booster dose of Arcturus' COVID-19 vaccine ARCT-154

Arcturus Therapeutics Holdings Inc.

Meiji Seika Pharma submitted a booster dose application for ARCT-154 in Japan based on Phase III data meeting primary endpoint.
This follows the April 28 NDA for primary immunization; ARCT-154 is a self-amplifying mRNA vaccine developed by Arcturus.
The Phase III trial (jRCT2071220080) compared ARCT-154 to COMIRNATY booster; no clinically significant safety concerns.
If approved, ARCT-154 would be a new COVID-19 vaccination option in Japan; distribution via CSL Seqirus agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.